Senior Account Manager of Applied StemCell, Inc
Advanced gene editing technologies are giving us unprecedented control over genomic modification. The emergence of nuclease-based technologies, such as CRISPR/Cas9, has enabled us to precisely edit virtually any location in the genome in a fraction of the time required for traditional approaches. In addition, integrase-based technologies, such as TARGATTTM, allow us to rapidly and site-specifically knock-in large expression cassettes, thereby enabling the rapid generation of overexpression models. Beyond their utility as pre-clinical research tools, both technologies hold great potential as next-generation therapies for the treatment of monogenic diseases. In his talk, Dr. Hilmer will discuss advances and challenges in the utilization of gene editing technologies for the development of both in vitro and in vivo pre-clinical research models.
